Literature DB >> 22386035

Prevalence of chronic kidney disease in China: a cross-sectional survey.

Luxia Zhang1, Fang Wang, Li Wang, Wenke Wang, Bicheng Liu, Jian Liu, Menghua Chen, Qiang He, Yunhua Liao, Xueqing Yu, Nan Chen, Jian-e Zhang, Zhao Hu, Fuyou Liu, Daqing Hong, Lijie Ma, Hong Liu, Xiaoling Zhou, Jianghua Chen, Ling Pan, Wei Chen, Weiming Wang, Xiaomei Li, Haiyan Wang.   

Abstract

BACKGROUND: The prevalence of chronic kidney disease is high in developing countries. However, no national survey of chronic kidney disease has been done incorporating both estimated glomerular filtration rate (eGFR) and albuminuria in a developing country with the economic diversity of China. We aimed to measure the prevalence of chronic kidney disease in China with such a survey.
METHODS: We did a cross-sectional survey of a nationally representative sample of Chinese adults. Chronic kidney disease was defined as eGFR less than 60 mL/min per 1·73 m(2) or the presence of albuminuria. Participants completed a lifestyle and medical history questionnaire and had their blood pressure measured, and blood and urine samples taken. Serum creatinine was measured and used to estimate glomerular filtration rate. Urinary albumin and creatinine were tested to assess albuminuria. The crude and adjusted prevalence of indicators of kidney damage were calculated and factors associated with the presence of chronic kidney disease analysed by logistic regression.
FINDINGS: 50,550 people were invited to participate, of whom 47,204 agreed. The adjusted prevalence of eGFR less than 60 mL/min per 1·73 m(2) was 1·7% (95% CI 1·5-1·9) and of albuminuria was 9·4% (8·9-10·0). The overall prevalence of chronic kidney disease was 10·8% (10·2-11·3); therefore the number of patients with chronic kidney disease in China is estimated to be about 119·5 million (112·9-125·0 million). In rural areas, economic development was independently associated with the presence of albuminuria. The prevalence of chronic kidney disease was high in north (16·9% [15·1-18·7]) and southwest (18·3% [16·4-20·4]) regions compared with other regions. Other factors independently associated with kidney damage were age, sex, hypertension, diabetes, history of cardiovascular disease, hyperuricaemia, area of residence, and economic status.
INTERPRETATION: Chronic kidney disease has become an important public health problem in China. Special attention should be paid to residents in economically improving rural areas and specific geographical regions in China. FUNDING: The Ministry of Science and Technology (China); the Science and Technology Commission of Shanghai; the National Natural Science Foundation of China; the Department of Health, Jiangsu Province; the Sichuan Science and Technology Department; the Ministry of Education (China); the International Society of Nephrology Research Committee; and the China Health and Medical Development Foundation. Copyright Â
© 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22386035     DOI: 10.1016/S0140-6736(12)60033-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  687 in total

1.  Effect of estrogen deficiency on the fixation of titanium implants in chronic kidney disease mice.

Authors:  S Zhang; Y Guo; H Zou; N Sun; D Zhao; W Liu; Y Dong; G Cheng; Q Yuan
Journal:  Osteoporos Int       Date:  2014-11-01       Impact factor: 4.507

2.  Study warns of burgeoning health burden of CKD in China.

Authors:  Susan J Allison
Journal:  Nat Rev Nephrol       Date:  2012-03-20       Impact factor: 28.314

3.  CKD Prevalence Varies across the European General Population.

Authors:  Katharina Brück; Vianda S Stel; Giovanni Gambaro; Stein Hallan; Henry Völzke; Johan Ärnlöv; Mika Kastarinen; Idris Guessous; José Vinhas; Bénédicte Stengel; Hermann Brenner; Jerzy Chudek; Solfrid Romundstad; Charles Tomson; Alfonso Otero Gonzalez; Aminu K Bello; Jean Ferrieres; Luigi Palmieri; Gemma Browne; Vincenzo Capuano; Wim Van Biesen; Carmine Zoccali; Ron Gansevoort; Gerjan Navis; Dietrich Rothenbacher; Pietro Manuel Ferraro; Dorothea Nitsch; Christoph Wanner; Kitty J Jager
Journal:  J Am Soc Nephrol       Date:  2015-12-23       Impact factor: 10.121

4.  Prevalence of hyperuricemia among Chinese adults: a national cross-sectional survey using multistage, stratified sampling.

Authors:  Hong Liu; Xiao-Min Zhang; Yan-Li Wang; Bi-Cheng Liu
Journal:  J Nephrol       Date:  2014-04-01       Impact factor: 3.902

5.  LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD.

Authors:  Wanghui Jing; Nosratola D Vaziri; Ane Nunes; Yasunori Suematsu; Ted Farzaneh; Mahyar Khazaeli; Hamid Moradi
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

Review 6.  Stem cell-based treatment of kidney diseases.

Authors:  Binbin Pan; Guoping Fan
Journal:  Exp Biol Med (Maywood)       Date:  2020-04-11

Review 7.  Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis.

Authors:  Dengpiao Xie; Jianting Wang; Xinping Wu; Mingquan Li
Journal:  Int Urol Nephrol       Date:  2018-08-02       Impact factor: 2.370

8.  A comparison between 2017 FAS and 2012 CKD-EPI equations: a multi-center validation study in Chinese adult population.

Authors:  Zhenzhu Yong; Fen Li; Xiaohua Pei; Xun Liu; Dan Song; Xiaoxuan Zhang; Weihong Zhao
Journal:  Int Urol Nephrol       Date:  2018-10-24       Impact factor: 2.370

9.  Matrix Metalloproteinase-7 Is a Urinary Biomarker and Pathogenic Mediator of Kidney Fibrosis.

Authors:  Dong Zhou; Yuan Tian; Ling Sun; Lili Zhou; Liangxiang Xiao; Roderick J Tan; Jianwei Tian; Haiyan Fu; Fan Fan Hou; Youhua Liu
Journal:  J Am Soc Nephrol       Date:  2016-09-13       Impact factor: 10.121

Review 10.  The global burden of chronic kidney disease: estimates, variability and pitfalls.

Authors:  Richard J Glassock; David G Warnock; Pierre Delanaye
Journal:  Nat Rev Nephrol       Date:  2016-12-12       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.